Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Flynn Daniel Lee Create: Alert

All | News | Filings
Date FiledTypeDescription
01/19/2023 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Sold 2,403 shares @ $21.2413, valued at $51k
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/18/2022 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Sold 1,366 shares @ $9.05, valued at $12.4k
01/20/2022 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Granted 20,500 shares @ $0
Granted 82,000 options to buy @ $8.27, valued at $678.1k
12/17/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/18/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/12/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/20/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/22/2020 4/A Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Exercised 10,106 options to buy @ $3.95, valued at $39.9k
01/21/2020 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Exercised 10,106 options to buy @ $3.95, valued at $39.9k
Exercised 56,800 options to buy @ $6.13, valued at $348.2k
12/13/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Sold 31,029 shares @ $60, valued at $1.9M
12/11/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Sold 30,175 shares @ $55, valued at $1.7M
Sold 28,822 shares @ $55, valued at $1.6M
Sold 93,930 shares @ $55, valued at $5.2M
Exercised 30,175 options to buy @ $1.89, valued at $57k
Exercised 28,822 options to buy @ $1.89, valued at $54.5k
Exercised 93,930 options to buy @ $1.89, valued at $177.5k
11/13/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/30/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/13/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/20/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Gifted 55,270 shares @ $0
02/25/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Exercised 24,500 options to buy @ $3.95, valued at $96.8k
02/01/2019 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/18/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Gifted 91,779 shares @ $0
Sold 152,629 shares @ $26, valued at $4M
Exercised 152,629 options to buy @ $1.89, valued at $288.5k
01/15/2019 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Sold 300 shares @ $26, valued at $7.8k
Exercised 300 options to buy @ $1.89, valued at $567
09/20/2018 4 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 4 on Deciphera Pharmaceuticals, Inc.
Txns: Converted 147,049 shares @ $0
Converted 22,070 preferred shares @ $0
Converted 1,494 preferred shares @ $0
Converted 1,392 preferred shares @ $0
Converted 1,071 preferred shares @ $0
Exercised 110,727 options to buy @ $1.89, valued at $209.3k
Exercised 625,607 options to buy @ $1.89, valued at $1.2M
Exercised 24,607 options to buy @ $1.89, valued at $46.5k
Exercised 139,029 options to buy @ $1.89, valued at $262.8k
Exercised 7,000 options to buy @ $3.95, valued at $27.7k
Exercised 39,550 options to buy @ $3.95, valued at $156.2k
09/20/2018 3 Flynn Daniel Lee (Chief Scientific Officer) has filed a Form 3 on Deciphera Pharmaceuticals, Inc.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy